Renaissance Technologies LLC increased its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 45.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 156,936 shares of the company's stock after acquiring an additional 49,200 shares during the quarter. Renaissance Technologies LLC owned about 0.23% of Replimune Group worth $1,900,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also bought and sold shares of REPL. Legal & General Group Plc lifted its position in Replimune Group by 42.1% in the 4th quarter. Legal & General Group Plc now owns 59,366 shares of the company's stock valued at $719,000 after acquiring an additional 17,597 shares in the last quarter. Aster Capital Management DIFC Ltd grew its position in Replimune Group by 8,798.9% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after buying an additional 8,183 shares during the period. Wells Fargo & Company MN increased its stake in shares of Replimune Group by 102.3% in the 4th quarter. Wells Fargo & Company MN now owns 77,371 shares of the company's stock worth $937,000 after purchasing an additional 39,121 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Replimune Group during the fourth quarter valued at about $205,000. Finally, Wellington Management Group LLP lifted its holdings in Replimune Group by 352.5% during the fourth quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company's stock valued at $13,282,000 after purchasing an additional 854,346 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.
Wall Street Analyst Weigh In
Several analysts recently issued reports on REPL shares. BMO Capital Markets lifted their target price on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, HC Wainwright boosted their target price on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Replimune Group has an average rating of "Buy" and a consensus price target of $19.43.
Check Out Our Latest Research Report on REPL
Replimune Group Stock Down 1.2 %
Shares of NASDAQ REPL traded down $0.12 during midday trading on Thursday, reaching $9.66. 135,703 shares of the company's stock traded hands, compared to its average volume of 780,096. The company has a market cap of $744.04 million, a price-to-earnings ratio of -3.15 and a beta of 1.26. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $17.00. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. The stock's 50 day simple moving average is $9.96 and its 200-day simple moving average is $11.62.
Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.
Replimune Group Company Profile
(
Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Further Reading
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
